Visual Performance After Implantation of an Aspheric Multifocal Diffractive Intraocular Lens
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Refractive Assessment
- Sponsor
- Hospital Oftalmologico de Brasilia
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- To evaluate distance, intermediate, and near vision after aspheric multifocal diffractive AcrySof® ReSTOR SN6AD1 intraocular lens (IOL) implantation.
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the distance, intermediate, and near vision after aspheric multifocal diffractive AcrySof® ReSTOR SN6AD1 intraocular lens (IOL) implantation.
Detailed Description
To evaluate distance, intermediate, and near vision after aspheric multifocal diffractive AcrySof® ReSTOR SN6AD1 intraocular lens (IOL) implantation. Prospective study of 50 patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation. Uncorrected distance vision acuity (UDVA), corrected distance visual acuity (CDVA), distance-corrected near visual acuity (DCNVA), and distance-corrected intermediate visual acuity (DCIVA) were measured postoperatively. A patient-satisfaction and visual phenomena questionnaire was administered at the end of the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Either gender
- •Diagnosis of cataracts both eyes
- •Pre-existing physical conditions that could skew visual results, such as Diabetes, Retinal detachment, Macular degeneration, or Cancer
- •Subjects must have \< 1.00 diopter of astigmatism
- •Biometry results for the Restore patients should target emmetropia or +0.25.
Exclusion Criteria
- •Central endothelial cell count less than 2000 cells/mm2 glaucoma or intraocular pressure greater than 21 mmHg amblyopia
- •Retinal abnormalities
- •Diabetes mellitus steroid or immunosuppressive treatment
- •Connective tissue diseases
Outcomes
Primary Outcomes
To evaluate distance, intermediate, and near vision after aspheric multifocal diffractive AcrySof® ReSTOR SN6AD1 intraocular lens (IOL) implantation.
Time Frame: 6 months